Larvol Delta - HiSCR100-as-the-New-Benchmark-A-Critical-MetaAnalysis-of-the-Gap-Between-Statistical-Significance-and-Complete-Disease-Resolution-in-Contemporary-Hidradenitis-Suppurativa-Trials-Povorcitinib-Izokibep-Bimekizumab

Bimzelx (bimekizumab-bkzx) - UCB

povorcitinib (INCB54707) - Incyte

izokibep (ABY-035) - Affibody

https://pagv3.virtual-meeting.org/eadv/eadvcongress2026/en-GB/pag/presentation/62498

Krish Lightwala

Aug 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next